Das Molekulardiagnostik-Unternehmen oncgnostics GmbH hat sich auf die Entwicklung von in-vitro diagnostischen Tests für Krebs spezialisiert.
Location: Germany, Thuringia, Jena
Investors 2
| Date | Name | Website |
| - | bm-t betei... | bm-t.de |
| - | High-Tech ... | htgf.de |
Mentions in press and media 12
| Date | Title | Description |
| 27.10.2023 | Hong Kong firm invests in Jena-based Oncgnostics GmbH | The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a 7‑digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer diagnostic Gyntect for the reliable detec... |
| 11.09.2023 | Oncgnostics Receives Seven Digit Euro Investment From Grande Bio-tech Co. | Oncgnostics, a Jena, Germany-based diagnostic company, received a seven digit euro investment from Grande Bio-tech Co. The company intends to use the funds to expand the distribution of its tests developed in the ASEAN countries. Led by Dr.... |
| 26.08.2022 | bm|t Investee-Partner oncgnostics enters the Chinese market | The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. The product is the first approved DNA methylation test for triage of HPV-positive cases in Ch... |
| 11.02.2015 | oncgnostics Closes Seven-Digit Euro Series A Financing Round | oncgnostics GmbH, a Jena, Germany-based molecular diagnostics company, closed a seven-digit Euro Series A financing round. The round was led by bm|t beteiligungsmanagement thüringen GmbH, with participation from Sparkasse Jena-Saale-Holzlan... |
| 17.04.2012 | oncgnostics Raises Seed Funding | oncgnostics GmbH, a Jena, Germany-based developer of molecular cancer diagnostics, has raised seed funding of undisclosed amount from High-Tech Gründerfonds and STIFT. The seed funding enables oncgnostics to develop diagnostically usable an... |
| - | oncgnostics expands business relations in Asia | Approval for cervical cancer screening test for the Chinese market expected in early 2020 / First contacts in Japan Middle: Dr Alfred Hansel and Dr Martina Schmitz; oncgnostics GmbH visiting the Chinese partner GeneoDx; (archive ima... |
| - | oncgnostics grants GynTect licence to SINOPHARM subsidiary CJMT | The Chinese pharmaceutical company Changchun Jienuo Medical Technology (CJMT), a subsidiary of the Chinese state-owned Sinopharm Group (www.sinopharm.com/en), has acquired an exclusive licence for the cervical cancer screeni... |
| - | Oncgnostics reaches funding limit of € 750,000 on seedmatch ahead of schedule | oncgnostics GmbH has already reached the funding limit of € 750,000 on the crowdfunding platform seedmatch 39 days before the end of the campaign. The first funding threshold of € 100,000 was exceeded just 2.5 hours after the star... |
| - | oncgnostics is “Innovator of the Year 2018 | The magazine brand eins honours oncgnostics GmbH from Jena as one of the most innovative companies in Germany in the industry “Chemistry, Pharma & Biotechnology”. More than 25,000 experts gave their verdict and selected th... |
| - | Biotech company oncgnostics receives one million euros after crowdfunding campaign | The biotech company oncgnostics GmbH (www.oncgnostics.com), provider of the cervical cancer test “GynTect”, ends its crowdinvesting campaign on Seedmatch very successfully. Even before the end of the investment period of 60 d... |
Show more